IMRIS (OTCMKTS:IMRSQ) vs. Nexalin Technology (NASDAQ:NXL) Financial Analysis

Nexalin Technology (NASDAQ:NXL) and IMRIS (OTCMKTS:IMRSQ) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Nexalin Technology and IMRIS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	1	0	0	2.00
IMRIS	0	0	0	0	0.00

Nexalin Technology presently has a consensus target price of $3.00, indicating a potential upside of 10.29%. Given Nexalin Technology’s stronger consensus rating and higher probable upside, analysts plainly believe Nexalin Technology is more favorable than IMRIS.

Valuation and Earnings

This table compares Nexalin Technology and IMRIS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$162,078.00	223.27	-$4.65 million	($0.64)	-4.25
IMRIS	N/A	N/A	N/A	N/A	N/A

IMRIS has lower revenue, but higher earnings than Nexalin Technology.

Institutional and Insider Ownership

0.6% of Nexalin Technology shares are held by institutional investors. 24.0% of Nexalin Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Nexalin Technology and IMRIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,407.98%	-187.59%	-167.21%
IMRIS	N/A	N/A	N/A

Summary

Nexalin Technology beats IMRIS on 5 of the 8 factors compared between the two stocks.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About IMRIS

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.